These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 24200276)

  • 21. Low serum concentrations of anti-tuberculosis drugs and determinants of their serum levels.
    Um SW; Lee SW; Kwon SY; Yoon HI; Park KU; Song J; Lee CT; Lee JH
    Int J Tuberc Lung Dis; 2007 Sep; 11(9):972-8. PubMed ID: 17705974
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Population pharmacokinetic modeling of isoniazid, rifampin, and pyrazinamide.
    Peloquin CA; Jaresko GS; Yong CL; Keung AC; Bulpitt AE; Jelliffe RW
    Antimicrob Agents Chemother; 1997 Dec; 41(12):2670-9. PubMed ID: 9420037
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. I. Single-dose study.
    Acocella G; Nonis A; Gialdroni-Grassi G; Grassi C
    Am Rev Respir Dis; 1988 Oct; 138(4):882-5. PubMed ID: 3202464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The disposition of antituberculous drugs in plasma of elderly patients. II. Isoniazid, rifampicin and pyrazinamide.
    Walubo A; Chan K; Woo J; Chan HS; Wong CL
    Methods Find Exp Clin Pharmacol; 1991 Oct; 13(8):551-6. PubMed ID: 1956210
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of pyrazinamide and rifampicin on isoniazid metabolism in rats.
    De Rosa HJ; Baldan HM; Brunetti IL; Ximenes VF; Machado RG
    Biopharm Drug Dispos; 2007 Sep; 28(6):291-6. PubMed ID: 17571294
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic and pharmacodynamic behaviour of antitubercular drugs encapsulated in alginate nanoparticles at two doses.
    Ahmad Z; Pandey R; Sharma S; Khuller GK
    Int J Antimicrob Agents; 2006 May; 27(5):409-16. PubMed ID: 16624533
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study.
    Acocella G; Nonis A; Perna G; Patane E; Gialdroni-Grassi G; Grassi C
    Am Rev Respir Dis; 1988 Oct; 138(4):886-90. PubMed ID: 3202465
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetics of isoniazid in pulmonary tuberculosis--a comparative study at two dose levels.
    Roy V; Tekur U; Chopra K
    Indian Pediatr; 1996 Apr; 33(4):287-91. PubMed ID: 8772902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The effect of hemodialysis on isoniazid, rifampin, pyrazinamide, and ethambutol.
    Malone RS; Fish DN; Spiegel DM; Childs JM; Peloquin CA
    Am J Respir Crit Care Med; 1999 May; 159(5 Pt 1):1580-4. PubMed ID: 10228130
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetics of first-line antituberculosis drugs in HIV-infected children with tuberculosis treated with intermittent regimens in India.
    Ramachandran G; Kumar AK; Bhavani PK; Kannan T; Kumar SR; Gangadevi NP; Banurekha VV; Sekar L; Ravichandran N; Mathevan G; Sanjeeva GN; Dayal R; Swaminathan S
    Antimicrob Agents Chemother; 2015 Feb; 59(2):1162-7. PubMed ID: 25487804
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efavirenz, tenofovir and emtricitabine combined with first-line tuberculosis treatment in tuberculosis-HIV-coinfected Tanzanian patients: a pharmacokinetic and safety study.
    Semvua HH; Mtabho CM; Fillekes Q; van den Boogaard J; Kisonga RM; Mleoh L; Ndaro A; Kisanga ER; van der Ven A; Aarnoutse RE; Kibiki GS; Boeree MJ; Burger DM
    Antivir Ther; 2013; 18(1):105-13. PubMed ID: 23043067
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tuberculosis drugs' distribution and emergence of resistance in patient's lung lesions: A mechanistic model and tool for regimen and dose optimization.
    Strydom N; Gupta SV; Fox WS; Via LE; Bang H; Lee M; Eum S; Shim T; Barry CE; Zimmerman M; Dartois V; Savic RM
    PLoS Med; 2019 Apr; 16(4):e1002773. PubMed ID: 30939136
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bioavailability of rifampicin, isoniazid and pyrazinamide in a triple drug formulation: comparison of plasma and urine kinetics.
    Gurumurthy P; Ramachandran G; Vijayalakshmi S; Kumar AK; Venkatesan P; Chandrasekaran V; Vjayasekaran V; Kumaraswami V; Prabhakar R
    Int J Tuberc Lung Dis; 1999 Feb; 3(2):119-25. PubMed ID: 10091876
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Plasma concentrations of isoniazid and rifampin are decreased in adult pulmonary tuberculosis patients with diabetes mellitus.
    Babalik A; Ulus IH; Bakirci N; Kuyucu T; Arpag H; Dagyildizi L; Capaner E
    Antimicrob Agents Chemother; 2013 Nov; 57(11):5740-2. PubMed ID: 23979746
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Therapeutic drug monitoring of isoniazid and rifampicin during anti-tuberculosis treatment in Auckland, New Zealand.
    Maze MJ; Paynter J; Chiu W; Hu R; Nisbet M; Lewis C
    Int J Tuberc Lung Dis; 2016 Jul; 20(7):955-60. PubMed ID: 27287650
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cure of tuberculosis despite serum concentrations of antituberculosis drugs below published reference ranges.
    Meloni M; Corti N; Müller D; Henning L; Gutteck U; von Braun A; Weber R; Fehr J
    Swiss Med Wkly; 2015; 145():w14223. PubMed ID: 26700218
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic exposure to rifampicin in patients with tuberculosis and advanced HIV disease during highly active antiretroviral therapy in Burkina Faso.
    Saleri N; Dembélé SM; Villani P; Carvalho AC; Cusato M; Bonkoungou V; Nacanabo R; Kouanda S; Comelli M; Regazzi M; Matteelli A
    J Antimicrob Chemother; 2012 Feb; 67(2):469-72. PubMed ID: 22028201
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of bioequivalence of rifampicin, isoniazid and pyrazinamide in a four drug fixed dose combination with separate formulations at the same dose levels.
    Agrawal S; Kaur KJ; Singh I; Bhade SR; Kaul CL; Panchagnula R
    Int J Pharm; 2002 Feb; 233(1-2):169-77. PubMed ID: 11897421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors Influencing Tuberculosis Treatment Outcome in Adult Patients Treated with Thrice-Weekly Regimens in India.
    Ramachandran G; Agibothu Kupparam HK; Vedhachalam C; Thiruvengadam K; Rajagandhi V; Dusthackeer A; Karunaianantham R; Jayapal L; Swaminathan S
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28242663
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring.
    Verbeeck RK; Günther G; Kibuule D; Hunter C; Rennie TW
    Eur J Clin Pharmacol; 2016 Aug; 72(8):905-16. PubMed ID: 27305904
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.